ClinicalTrials.gg
RecruitingNCT07154654Updated Sep 23, 2025

Prospective, Long Term, Observational Study (Patient Registry) of Paediatric Myotonic Disorders

An observational study in Myotonic Disorders, sponsored by Lupin Ltd.. Recruiting at 1 site in France. Open to participants aged Up to 6 Years. Per ClinicalTrials.gov, last updated 2025-09-23.

Sponsored by Lupin Ltd. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10
Ages
Up to 6 Years
Sex
All
01

Study summary

This is a prospective, open-label, multi-centre, single arm, registry study to collect standard relevant clinical and epidemiological data during routine medical evaluation and treatment in paediatric patients with myotonic disorders who are being treated with mexiletine therapy according to the physician.

Read the detailed description

This is a prospective, open-label, multi-centre, single arm, registry study to collect standard relevant clinical and epidemiological data during routine medical evaluation and treatment in paediatric patients with myotonic disorders who are being treated with mexiletine therapy according to the physician.

Patients who meet the eligibility criteria will be enrolled in 2 cohorts by age groups although cohorts are not enrolled sequentially (cohort definition is to assure minimum requirements for meeting PIP agreements).

Cohort 1 - Infants and children aged between 6 months to less than 6 years. Cohort 2 - Neonates and infants from birth to less than 6 months. The overall treatment duration follow-up for each cohort will be at least 2 years.

02

Conditions studied

  • Myotonic Disorders
03

In context

Lead sponsor

Lupin Ltd. is the lead sponsor of 16 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 6 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

The study population will include male and female children from birth to less than 6 years of age with clinical symptoms or signs of myotonic disorders, normal electrocardiogram (ECG) exam and genetic confirmation of the diagnosis i.e., non-dystrophic myotonia (NDM), or myotonic dystrophy (DM) type 1 (DM1), or DM type 2 (DM2), and who comply with the inclusion / exclusion criteria.

Patients will be enrolled consecutively at each site in order to minimize selection bias

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients from birth to less than 6 years
  2. A genetically confirmed diagnosis of NDM or DM (DM1or DM2), as per the treating clinician.
  3. Presence of clinical symptoms of myotonia (hand grip myotonia, myotonia in the leg muscles, any other myotonia symptoms) to be confirmed by the treating clinician.
  4. Patients already receiving mexiletine treatment or who are clinically considered for mexiletine treatment as per the treating physician judgement.
  5. No history of or significant cardiac abnormalities as determined by a cardiologist's assessment of the and echocardiogram performed prior to enrolment in the study or as per the treating physician standard of care (NaMuscla SmPC, 2023)
  6. No known history or signs and symptoms of any significant liver disorder as per treating physician.
  7. No known abnormal laboratory investigations for haematology, biochemistry, and urinalysis values at screening (or based on values obtained within 3 months prior to screening in patient's medical record) that could affect the study objectives as judged by the treating physician.
  8. Parent or legal guardian able to provide consent/assent to study participation and to sign the written or non-opposition as per local regulatory requirements prior to study entry and perform any study-related activity. -

Exclusion criteria

Exclusion Criteria:

  1. Any to mexiletine as listed in the Namuscla Summary of Product Characteristics (SmPC) (NaMuscla SmPC, 2023)

    1. to the active substance, or to any of the
    2. Hypersensitivity to any local anaesthetic
    3. Ventricular tachyarrhythmia
    4. Complete heart block (i.e., third-degree atrioventricular block) or any heart block susceptible to evolve to complete heart block (first-degree atrioventricular block with markedly prolonged PR interval (≥ 200 ms) and/or wide QRS complex (≥ 120 ms), second-degree atrioventricular block, bundle branch block, bifascicular and trifascicular block),
    5. > 450ms
    6. Myocardial infarction (acute or past), or abnormal Q-waves
    7. Symptomatic coronary artery disease
    8. Heart failure with \<50%
    9. Atrial tachyarrhythmia, fibrillation or flutter
    10. Sinus node dysfunction (including sinus rate \< 50 bpm)
    11. Co-administration with medicinal products inducing torsades de pointes.
    12. Co-administration with medicinal products with narrow therapeutic index
  2. Any other neurological or psychiatric condition that might affect the study assessments, as per the treating clinician.
  3. Any illness, laboratory findings, , or other clinical symptoms, which in the opinion of the treating physician could affect the patient's optimal participation in the study
  4. Receiving strong inducers or inhibitors of CYP2D6 or CYP1A2 or planned to receive them, during the subject participation (See section 4.1.5.1 Prohibited medications).
  5. Any concurrent illness, or medications which could affect the muscle function, and confound the results according to the treating physician.
  6. Seizure disorder, diabetes mellitus requiring treatment by insulin.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • Cohort 1

    Infants and children aged between 6 months to less than 6 years.

    Drug: Mexiletine

  • Cohort 2

    Neonates and infants from birth to less than 6 months.

    Drug: Mexiletine

Interventions

06

What researchers measure

Primary outcomes

  1. To assess long-term safety by collection of SAEs, AEs, AESIs, changes in frequency, treatment interruptions

    Number and frequency of adverse events (AEs), serious adverse events (SAEs) and AE leading to treatment discontinuation, throughout the study while on treatment with mexiletine; Incidence of adverse events of special interest (AESI), namely: Severe Cutaneous Adverse Reactions (SCARs) \& Cardiac arrhythmia. Increased frequency of seizure episodes in patients with epilepsy; Any changes in frequency, treatment interruptions of mexiletine

    Time frame: Baseline to 24 months

Secondary outcomes

  1. To assess the suitability of mexiletine administration

    To assess the suitability of mexiletine administration using available formulations including, where appropriate, capsules or opening and sprinkling contents in food or drink according to the child´s age (from birth to less than 6 years) and ability to swallow.

    Time frame: Baseline to 24 months

  2. To understand how mexiletine is used by clinicians

    To understand how mexiletine is used by clinicians who have previously decided to use mexiletine for the treatment of myotonia in myotonic disorder patients, from birth to less than 6 years over a at least 2 years period, to establish risk:benefit conclusions.

    Time frame: Baseline to 24 months

  3. Description over time of outcomes of mexiletine use

    Description over time of outcomes of mexiletine use including dosing, formulation used, method of administration, acceptability and palatability as per the data collected by the treating physician according to age and cohort.

    Time frame: Baseline to 24 months

  4. The treating physician with elaborate a brief text with risk-benefit conclusions

    Description over time of any efficacy outcomes obtained from clinically indicated tests as per the treating physician typical clinical practice and according to patient's age and cohort.

    Time frame: Baseline to 24 months

Other outcomes

  1. Description over time of any efficacy outcomes

    Description over time of any efficacy outcomes obtained from clinically indicated tests as per the treating physician typical clinical practice and according to patient's age and cohort.

    Time frame: Baseline to 24 months

  2. Clinical Global Impression (CGI) Scores

    Clinical Global Impression (CGI) Scores given to caregivers and assessed by the investigators. Efficacy will be evaluated on a 4-point scale as very efficient, good, fair or poor.

    Time frame: Baseline to 24 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for Nov 2027, 25 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2025
First posted
Sep 4, 2025
StartEst.
Sep 30, 2025
Primary completionEst.
Nov 22, 2027
CompletionEst.
Feb 22, 2028
Last update
Sep 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07154654
Lead sponsor
Lupin Ltd.
Responsible party
Sponsor
First posted
Sep 4, 2025
Start date
Sep 30, 2025 (estimated)
Primary completion
Nov 22, 2027 (estimated)
Completion
Feb 22, 2028 (estimated)
Last update
Sep 23, 2025

Study contacts

Nikki Adetoro
Contact
nikkiadetoro@lupin.com
4434474534
Catharine Sarret, MD
principal investigator · University Hospital, Clermont-Ferrand

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion